Novartis, Pharmax to enhance access to quality medicines across UAE strategy

Novartis, Pharmax to enhance access to quality medicines across UAE strategy

The agreement will cover the commercialisation of oral antidiabetic and oral antihypertensive medicines to enhance care and treatment outcomes for these conditions.

Published: Thu 3 Mar 2022, 10:22 PM Last updated: Thu 3 Mar 2022, 10:36 PM

Novartis, a leading global medicines company, and ranked among the world’s top pharmaceutical companies announced a strategic partnership with UAE-based Pharmax Pharmaceuticals.

In line with the vision of UAE’s Ministry of Health and Prevention to encourage partnerships between research-based pharmaceutical companies and manufacturers in the UAE, the collaboration covers the commercialisation and co-marketing of Novartis products to Pharmax to enhance patient access to medicines and treatments in a range of Cardiometabolic diseases such as diabetes and hypertension.

Both companies formalised their partnership at a signing ceremony held at the Swiss Pavilion, Dubai Expo 2020 in the presence of Massimo Baggi, Ambassador of Switzerland to UAE and Bahrain; Marwan Abdul Aziz, Managing Director at Dubai Science Park; Mohamed Ezz Eldin, President and Head of Gulf Cluster at Novartis Pharmaceuticals; Fahad Al Qassim, Chairman of Pharmax, and Madhukar Tanna, CEO at Pharmax Pharmaceuticals.

“Our vision is to foster an effective and sustainable healthcare system that contributes to the wellbeing of society, and key partnerships in the private sector are critical